MX347019B - Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma de tumores de celulas b. - Google Patents

Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma de tumores de celulas b.

Info

Publication number
MX347019B
MX347019B MX2013013455A MX2013013455A MX347019B MX 347019 B MX347019 B MX 347019B MX 2013013455 A MX2013013455 A MX 2013013455A MX 2013013455 A MX2013013455 A MX 2013013455A MX 347019 B MX347019 B MX 347019B
Authority
MX
Mexico
Prior art keywords
treatment
cell malignancies
maytansinoid immunoconjugate
immunoconjugate antibody
symptoms
Prior art date
Application number
MX2013013455A
Other languages
English (en)
Other versions
MX2013013455A (es
Inventor
Morariu Rodica
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347019(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2013013455A publication Critical patent/MX2013013455A/es
Publication of MX347019B publication Critical patent/MX347019B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un inmunoconjugado de maitansinoide anti-CD19 para tratar el síntoma de tumores de células B CD19, en particular el linfoma no-Hodgkin.
MX2013013455A 2011-05-17 2012-05-16 Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma de tumores de celulas b. MX347019B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290232A EP2524929A1 (en) 2011-05-17 2011-05-17 Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PCT/EP2012/059141 WO2012156455A1 (en) 2011-05-17 2012-05-16 Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms

Publications (2)

Publication Number Publication Date
MX2013013455A MX2013013455A (es) 2014-02-17
MX347019B true MX347019B (es) 2017-04-07

Family

ID=46085972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013455A MX347019B (es) 2011-05-17 2012-05-16 Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma de tumores de celulas b.

Country Status (30)

Country Link
US (2) US9555126B2 (es)
EP (2) EP2524929A1 (es)
JP (4) JP6050328B2 (es)
KR (1) KR20140043388A (es)
CN (2) CN107007840A (es)
AR (1) AR086412A1 (es)
AU (3) AU2012258254B2 (es)
BR (1) BR112013029330A8 (es)
CA (1) CA2835738A1 (es)
CL (1) CL2013003272A1 (es)
CO (1) CO6821893A2 (es)
CR (1) CR20130593A (es)
DO (1) DOP2013000260A (es)
EA (1) EA028574B1 (es)
EC (1) ECSP13013084A (es)
GT (1) GT201300276A (es)
IL (3) IL229380B (es)
MA (1) MA35180B1 (es)
MX (1) MX347019B (es)
MY (1) MY163736A (es)
NI (1) NI201300119A (es)
PE (1) PE20141018A1 (es)
PH (1) PH12017501368A1 (es)
SG (2) SG194894A1 (es)
TN (1) TN2013000468A1 (es)
TW (3) TW201726167A (es)
UA (1) UA114401C2 (es)
UY (1) UY34077A (es)
WO (1) WO2012156455A1 (es)
ZA (1) ZA201309400B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
HUE055856T2 (hu) 2013-08-30 2021-12-28 Immunogen Inc Antitestek és vizsgálatok a folsavreceptor 1 kimutatására
CN105837689B (zh) * 2015-01-13 2020-06-19 博生吉安科细胞技术有限公司 抗cd19单克隆抗体及其制备方法
WO2016180941A1 (en) * 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
CN107660151B (zh) 2015-05-26 2022-03-11 莫佛塞斯公司 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
CN107921129B (zh) 2015-08-21 2022-05-27 莫佛塞斯公司 组合及其用途
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
FI3380525T3 (fi) 2015-11-25 2024-01-30 Immunogen Inc Lääkeformulaatioita ja niiden käyttömenetelmiä
EP3916392B1 (en) 2016-05-30 2024-05-01 Incyte Corporation Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
IL263764B1 (en) 2016-06-27 2024-05-01 Morphosys Ag Anti-CD19 antibody formulations
EP3532098B1 (en) 2016-10-28 2021-04-07 MorphoSys AG Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
CA3057749A1 (en) * 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
US11497769B2 (en) * 2017-09-21 2022-11-15 WuXi Biologics Ireland Limited Anti-CD19 antibodies
SG11202005541QA (en) 2018-01-12 2020-07-29 Immunogen Inc Methods for antibody drug conjugation, purification, and formulation
JP2022529854A (ja) 2019-04-26 2022-06-24 イミュノジェン・インコーポレーテッド カンプトテシン誘導体
AU2020267823A1 (en) 2019-05-03 2021-11-11 Incyte Corporation Anti-CD19 therapy in patients having a limited number of NK cells
EP4051315A1 (en) 2019-10-31 2022-09-07 MorphoSys AG Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
EP4051710A1 (en) 2019-10-31 2022-09-07 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
CA3153636A1 (en) * 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
CN111303287B (zh) * 2019-12-05 2022-05-20 常州费洛斯药业科技有限公司 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用
CA3181827A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
CA3194386A1 (en) 2020-10-06 2022-04-14 Ying Ding Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
WO2022117799A2 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CR20170291A (es) * 2003-05-20 2017-07-27 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
PT2066349E (pt) * 2006-09-08 2012-07-02 Medimmune Llc Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes
NZ594177A (en) * 2009-02-05 2014-02-28 Immunogen Inc Novel benzodiazepine derivatives
KR101725170B1 (ko) * 2009-05-06 2017-04-10 바이오테스트 아게 Ｃｄ１３８을 표적으로 하는 면역접합체의 용도
US20110097345A1 (en) * 2009-10-21 2011-04-28 Immunogen Inc. Novel dosing regimen and method of treatment
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab

Also Published As

Publication number Publication date
NI201300119A (es) 2014-02-28
ECSP13013084A (es) 2014-01-31
MX2013013455A (es) 2014-02-17
EA028574B1 (ru) 2017-12-29
UA114401C2 (uk) 2017-06-12
US20170196988A1 (en) 2017-07-13
TW201726167A (zh) 2017-08-01
CA2835738A1 (en) 2012-11-22
PH12017501368A1 (en) 2018-01-29
EP2524929A1 (en) 2012-11-21
MY163736A (en) 2017-10-31
AU2018201504A1 (en) 2018-03-22
TW201249460A (en) 2012-12-16
IL229380B (en) 2018-02-28
EP2710034A1 (en) 2014-03-26
AU2012258254A1 (en) 2013-05-02
PE20141018A1 (es) 2014-08-27
IL229380A0 (en) 2014-01-30
EA201391714A1 (ru) 2014-03-31
IL257475A (en) 2018-06-28
BR112013029330A8 (pt) 2018-01-30
JP2018021020A (ja) 2018-02-08
CN107007840A (zh) 2017-08-04
CO6821893A2 (es) 2013-12-31
AU2012258254B2 (en) 2016-04-21
TWI601537B (zh) 2017-10-11
US9555126B2 (en) 2017-01-31
JP2017081926A (ja) 2017-05-18
DOP2013000260A (es) 2014-01-31
MA35180B1 (fr) 2014-06-02
TN2013000468A1 (en) 2015-03-30
WO2012156455A1 (en) 2012-11-22
UY34077A (es) 2013-01-03
US20140072587A1 (en) 2014-03-13
AR086412A1 (es) 2013-12-11
JP6050328B2 (ja) 2016-12-21
JP2014515036A (ja) 2014-06-26
BR112013029330A2 (pt) 2016-11-29
TW201834687A (zh) 2018-10-01
GT201300276A (es) 2015-03-23
KR20140043388A (ko) 2014-04-09
SG10201609729VA (en) 2016-12-29
CR20130593A (es) 2014-01-09
CN103547596A (zh) 2014-01-29
AU2016206317A1 (en) 2016-08-11
IL263728A (en) 2019-01-31
JP6181273B2 (ja) 2017-08-16
CL2013003272A1 (es) 2014-08-01
SG194894A1 (en) 2013-12-30
ZA201309400B (en) 2015-04-29
JP2019142961A (ja) 2019-08-29
NZ618012A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
PH12017501368A1 (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
EP2569434A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
TN2015000050A1 (en) Methods of treating a tauopathy
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
EA201171367A1 (ru) Винилиндазолильные соединения
MX2013006365A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MX354988B (es) Formulaciones de anticuerpo y metodos.
NZ601588A (en) Methods for treating breast cancer
GB201109238D0 (en) Antibodies
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2013006184A (es) Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.
MX2016010948A (es) Composiciones y metodos para identificar neoplasias de celulas b sensibles a terapia de reduccion de celulas b.
NZ622728A (en) Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
TN2013000507A1 (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.
TH153141A (th) การใช้แอนติ-cd19 เมย์แทนซินซิดอิมมูโนคอนจูเกตแอนติบอดีสำหรับการรักษาอาการมะเร็งบีเซลล์
UA57317U (ru) Применение корвитина в качестве средства для лечения острой черепно-мозговой травмы
UA61635U (ru) Применение пропранолола как препарата для лечения гемангиом у детей

Legal Events

Date Code Title Description
FG Grant or registration